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Introduction
Type 2 diabetes mellitus (DM) is a disease with multiple
complications and premature mortality, and is suggested
to be equivalent to myocardial infarction with regard to
the significantly increased risk of future or recurrent
cardiovascular events.1 Hypertensive patients frequently
have associated insulin resistance and are predisposed
to DM with increased cardiovascular risk.2–4 In treated
hypertensive subjects, new-onset DM (which usually
takes a considerable duration of time to develop) could
be directly associated with cardiovascular events5 or
carry a risk of subsequent cardiovascular disease simi-
lar to that in previously known diabetic patients.6
In addition to increased body mass index, impaired
glucose tolerance (IGT) could be directly related to
future onset of type 2 DM.7 Impaired fasting glucose
(IFG), while is more easily and commonly measured,
has also been proven to be an important risk factor 
for the development of type 2 DM in healthy subjects
and in hypertensive patients under treatment.8–10
Nevertheless, not all subjects with increased body mass
index, IGT or IFG may go on to develop DM. Com-
prehensive risk stratification with both glucose and
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non-glucose parameters may be required to more
efficiently identify the subjects at most risk of devel-
oping type 2 DM. It could be particularly important
to patients with untreated, newly diagnosed essential
hypertension not only due to the potential prognostic
impacts4,6 but also because of concern that some anti-
hypertensive medications may increase the risk of
subsequent DM in the future.11–13
It has been suggested that some non-glucose indi-
cators may be related to the onset of type 2 DM in
specific cohorts.14–17 The loss of diurnal changes in
blood pressure (BP), while being linked to increased
cardiovascular risk in common hypertensives,14,15 is
associated with the presence of abnormal glucose metab-
olism in young essential hypertensives.16 Elevated ala-
nine aminotransferase (ALT), one of the liver enzymes,
was associated with decreased hepatic insulin sensitiv-
ity and predicted the development of type 2 DM in
Pima Indians.17 In some other cohorts, endothelial dys-
function may also be detected before the development
of type 2 DM.18–20 However, it is not known whether
the above parameters can predict the onset of type 
2 DM in untreated, newly diagnosed essential hyper-
tensives. This study was therefore conducted to prospec-
tively evaluate the prognostic impacts of both glucose
(fasting plasma glucose [FPG] level) and non-glucose
(blood biochemistry, endothelial function, diurnal BP
pattern) parameters on the future onset of type 2 DM
in a cohort of ethnic Chinese patients with newly
diagnosed essential hypertension in Taiwan.
Methods
Patient populations
Between May 1997 and October 2000, a series of 298
consecutive subjects suspected to have hypertension
were prospectively investigated for a definite diagno-
sis of hypertension by a comprehensive protocol at
the hypertension clinic of a national medical center in
Taipei, Taiwan. In each subject, hypertension was eval-
uated and diagnosed according to the guidelines in
The Sixth Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. Serial work-up was also done to
detect the potential presence of secondary hyperten-
sion including renovascular hypertension, primary aldos-
teronism, pheochromocytoma, Cushing syndrome,
hyperthyroidism, hypothyroidism, and others. The pres-
ence of type 2 DM was determined by FPG level
> 7.8 mmol/L in 2 separate tests.
Then, patients with newly diagnosed essential
hypertension were prospectively enrolled if they could
fulfill the diagnostic criteria and had not taken regular
antihypertensive medication prior to the study. Pa-
tients were excluded if they had clinical evidence of
secondary hypertension, type 1 or 2 DM, significant
cardiovascular disease such as coronary artery disease,
congenital heart disease, valvular heart disease, conges-
tive heart failure, stroke, peripheral arterial occlusive
disease, or other significant systemic diseases includ-
ing liver dysfunction (elevated value 2-fold above the
normal upper limit) and renal impairment (serum cre-
atinine level >1.7mg/dL). Since the American Diabetes
Association (ADA) criteria for DM were renewed 
in 2003 (FPG > 7.0 mmol/L in 2 separate tests),21
the original records were reviewed again in 2005. 
Patients with initial FPG level > 7.0 mmol/L in 2 sep-
arate tests were also retrospectively excluded. The
study protocol was approved by the Human Research
Committee of the hospital. A written informed con-
sent was obtained from each patient before the study.
BP and heart rate monitoring
All patients received ambulatory BP monitoring for
24 hours by the cuff-oscillometric method with the
SpaceLabs 90207 ambulatory BP monitor (SpaceLabs
Medical Inc., Redmond, WA, USA). During the pro-
cedure, the monitor was programmed to automatically
record blood pressure every 20 minutes during the
daytime (07:00 A.M. to 10:00 P.M.) and every 30 min-
utes during the night (10:00 P.M. to 07:00 A.M.).
The mean BP at daytime and that at nighttime were
calculated individually and analyzed for diurnal varia-
tion. In addition, patients were instructed to maintain
their regular activities during the day and to follow the
sleep schedule at night during the recording period.
Vascular endothelial function evaluation 
by plethysmography
A mercury-in-silastic strain-gauge venous plethysmo-
graph (Hokanson EC 5R; Hokanson, Bellevue, WA,
USA) was used to measure endothelial function of
resistance vessels. The method has been described in
detail in our previous study.18 In brief, the patient was
lying on a comfortable bed with forearm suspended
above the level of the heart. The strain-gauge was
placed over the right forearm, and a small cuff was
inflated over the right wrist with suprasystolic pres-
sure at 1 minute before and maintained throughout
the measurement period. Meanwhile, venous return
of forearm was prevented by a rapid-cuff inflator
(Hokanson E-20) which afforded 50 mmHg pressure,
and forearm blood flow (FBF) was calculated from
the increased rate of the volume (mL/100 mL fore-
arm volume per minute). A 7-minute flow recording
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was repeated every 15 seconds for 2 minutes. An aver-
age of ≥ 3 curves for steady blood flow was used for
the mean value of basal FBF. Five minutes after mea-
surement of basal FBF, the upper arm cuff was inflated
to a suprasystolic pressure (> 10 mmHg above systolic
BP) for 5 minutes, which induced forearm ischemia.
Then, the cuff was released and the FBF during reac-
tive hyperemia was recorded every 15 seconds for 
2 minutes. Peak value was usually obtained within 
the initial 30 seconds. The average of the highest 2 of
the initial 3 recordings was defined as peak reactive
hyperemic blood flow. Finally, to evaluate endothelial-
independent vasodilatation effect, nitroglycerin 0.6 mg
was administered sublingually after FBF returned to
the baseline level. The measurements of BP and FBF
were repeated as mentioned above.
Blood sampling
In each patient, a 10-mL blood sample was collected
from peripheral vessels in the morning hours after an
overnight fast. The blood sample was either analyzed
immediately or stored in a −20°C refrigerator until
analysis for other biomarkers. Plasma glucose was
measured by an automatic chemistry analyzer from
PrismaSystems Corp. (Rome, NY, USA). Lipid profiles
including total cholesterol (TC), triglyceride (TG),
and other biochemical parameters were measured using
a Hitachi 7600-310 autoanalyzer (Hitachi, Tokyo,
Japan).
Clinical follow-up
All the patients were prospectively followed-up at our
hypertension clinics every 1–3 months for at least 
5 years. Every patient was treated with at least 1 anti-
hypertensive medication according to the contempo-
rary antihypertensive guidelines (6th and 7th Joint
National Committee guidelines or World Health Orga-
nization guidelines). In each patient, use of the new
antihypertensive drugs such as calcium channel block-
ers, angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin II receptor blockers (ARBs) along
with the old drugs including β-adrenergic blockers,
α-adrenergic blockers, and diuretics to achieve the goal
of guideline-recommended BP (< 140/90 mmHg) was
encouraged. The regular antihypertensive medications
used for more than 6 months were recorded. During
the follow-up period, blood biochemistry studies in-
cluding FPG, lipid profiles, liver and renal function
tests were scheduled every 3–6 months according to
the patient’s individual condition. Clinical events in-
cluding death, acute myocardial infarction, stroke,
heart failure, coronary artery disease, or other signifi-
cant systemic diseases were recorded if there were any.
The new onset of type 2 DM was confirmed accord-
ing to ADA criteria (FPG > 7.0 mmol/L in 2 separate
tests).21 Between February and October 2006, all the
patients were interviewed again either at clinics or via
telephone. The medical records were also reviewed by
an independent investigator blind to their medical
history and clinical condition.
Statistical analysis
Data are presented as mean ± standard error of the
mean unless otherwise indicated. The numerical vari-
ables and frequencies between groups were compared
by Student’s t test, Mann-Whitney U test, and/or χ2
test as appropriate. Because of skewed distribution and
in order to evaluate the prediction ability of parameters
for new-onset DM, quartiles were used for further
analysis. The Kaplan-Meier method with log-rank test
was performed to assess the difference in the time
course of disease-free survival between these groups.
Univariate and multivariate Cox proportional hazards
regression analyses were used to determine the inde-
pendent predictors of end point in each group if
appropriate. A p value < 0.05 was defined as statisti-
cally significant.
Results
Patient characteristics and clinical follow-up
A total of 106 consecutive non-diabetic patients with
newly diagnosed essential hypertension were studied.
At baseline, their mean age was 55.1 ± 1.0 years and
56% were males. The mean duration of follow-up was
70.6 ± 13.9 months. All the patients survived through
the follow-up period. Of them, 6 patients (3 males, 
3 females) developed new-onset DM, 1 during the
3rd year and the other 5 during the 5th and 6th years of
follow-up. Table 1 shows the baseline clinical charac-
teristics of the 100 patients without and the 6 patients
with new-onset DM. Patients with new-onset DM
had higher FPG level (p = 0.003) and serum ALT
(p = 0.008) at baseline than those without. Eighteen
(18.0%) of the patients without new-onset DM and 
3 (50.0%) of the patients with new-onset DM had
metabolic syndrome (p = 0.056).
During follow-up, most of the patients’ systolic BP
were kept around 120–150 mmHg and diastolic BP
around 60–95mmHg by various antihypertensive med-
ications (usually calcium channel blockers, β-adrenergic
blockers, ACEIs and ARBs, either alone or in combi-
nation). However, thiazide diuretics and α-adrenergic
blockers were much less used unless in combination
with other medications. The initial antihypertensive
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medications and the number of drugs used were simi-
lar between the 6 patients with and the 100 without
new-onset DM.
Through the follow-up period, there were 8 patients
with cardiovascular events, including 3 strokes, 1 acute
myocardial infarction, 1 hospitalization for congestive
heart failure, and another 3 with stable coronary artery
disease proven by coronary angiography during the
follow-up period. Among the 6 patients with new-onset
DM, 1 experienced stroke, 1 had acute myocardial
infarction, and another 1 had stable coronary artery
disease following the onset of DM. These patients did
not have the history of hepatitis during the follow-up
period. The incidence of hard cardiovascular events
including death, acute myocardial infarction and
stroke was 4% in patients without and 33% in those
with new-onset type 2 DM (p < 0.05).
24-hour ambulatory blood pressure monitoring
The differences in BP levels between daytime and
nighttime (day-night difference) are also presented in
Table 1. The difference was calculated by daytime BP
minus nighttime BP then divided by daytime BP. Base-
line day-night difference in diastolic BP (p = 0.004)
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Table 1. Baseline characteristics in 6 hypertensive patients with and 100 without new-onset diabetes mellitus*
No DM (n = 100) New-onset DM (n = 6) p†
Men/Women 56/44 3/3 0.774
Age (yr) 54.9 ± 1.1 57.5 ± 4.6 0.613
BMI (kg/m2) 26.3 ± 0.3 26.2 ± 0.8 0.827
Waist circumference (cm) 86.3 ± 11.2 88.4 ± 12.9 0.657
Hip circumference (cm) 100.3 ± 8.9 101.5 ± 8.3 0.578
Metabolic syndrome 18 (18.0) 3 (50.0) 0.056
Blood chemistry
Total cholesterol (mg/dL) 202.2 ± 4.1 230.0 ± 21.2 0.196
Triglyceride (mg/dL) 133.2 ± 7.2 143.2 ± 13.1 0.286
FPG (mmol/L) 5.3 ± 0.1 6.2 ± 0.2 0.005‡
ALT (U/L) 28.4 ± 3.7 39.1 ± 4.9 0.010‡
AST (U/L) 23.8 ± 1.2 28.5 ± 3.7 0.082
BUN (mg/dL) 14.9 ± 0.4 18.2 ± 2.5 0.224
Creatinine (mg/dL) 1.1 ± 0.1 1.0 ± 0.0 0.728
24-hour BP recording
Daytime (07:00 A.M. to 10:00 P.M.)
Systolic BP (mmHg) 150.9 ± 9.6 151.8 ± 8.2 0.853
Diastolic BP (mmHg) 100.4 ± 6.7 98.5 ± 4.3 0.253
Mean BP (mmHg) 116.7 ± 7.2 114.7 ± 5.3 0.632
Pulse pressure (mmHg) 50.2 ± 0.8 55.2 ± 2.1 0.043‡
Heart rate (beat/min) 73.1 ± 5.4 74.4 ± 5.7 0.283
Nighttime (10:00 P.M. to 07:00 A.M.)
Systolic BP (mmHg) 141.7 ± 8.3 145.4 ± 7.5 0.246
Diastolic BP (mmHg) 91.2 ± 4.5 97.6 ± 4.6 0.373
Mean BP (mmHg) 105.7 ± 6.4 112.7 ± 5.1 0.272
Pulse pressure (mmHg) 49.1 ± 0.9 51.0 ± 2.4 0.347
Heart rate (beat/min) 67.3 ± 4.4 68.5 ± 5.5 0.284
Day-night BP difference (%)
Systolic BP 5.9 ± 0.7 3.4 ± 1.5 0.235
Diastolic BP 7.9 ± 0.8 0.7 ± 1.4 0.006‡
Mean BP 6.9 ± 0.7 1.4 ± 1.4 0.019‡
FBF by plethysmography (mL/100 mL/min) 
Baseline 4.6 ± 0.2 3.8 ± 0.5 0.534
At peak reactive hyperemia 15.6 ± 0.4 13.6 ± 0.9 0.240
After sublingual NTG 4.6 ± 0.2 3.6 ± 0.3 0.247
*Data presented as n or mean ± standard deviation or n (%); †Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables;
‡p < 0.05. DM = diabetes mellitus; BMI = body mass index; FPG = fasting plasma glucose; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
BUN = blood urea nitrogen; BP = blood pressure; FBF = forearm blood flow; NTG = nitroglycerin.
and that in mean BP (p = 0.016) but not systolic BP
were significantly reduced in patients with new-onset
DM compared to the patients without. Daytime pulse
pressure was also increased in the former compared
with the latter group. There were no differences in
baseline heart rate, either in daytime or nighttime,
between the 2 groups.
Basal and hyperemic FBF
As shown in Table 1, basal FBF was similar between
patients with and without new-onset DM (p = 0.356).
FBF significantly increased during reactive hyperemia
in both groups (p < 0.001, respectively). There was no
difference in FBF either during peak reactive hyper-
emia or after sublingual nitroglycerin administration
between the 2 groups.
Antihypertensive medications during the
follow-up period
All patients were treated according to the guidelines
from The Sixth Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure or guidelines from the World
Health Organization. At final follow-up, the morning
office BP was < 160/100 mmHg in all patients, < 140/
90 mmHg in 90 patients (85%) and < 130/80 mmHg
in 62 patients (58%). There were no differences in the
final office BP and in the antihypertensive medications
prescribed between patients with and those without
new-onset DM during the follow-up period. The aver-
age number of antihypertensive medications was 
2.2 in patients with new-onset DM and 2.3 in those
without. Among the 6 patients with new-onset DM, 
33% were treated with thiazide diuretics, 33% with 
β-adrenergic blockers, 33% with α-adrenergic blockers,
50% with ACEIs or ARBs, and 67% with calcium chan-
nel blockers before the onset of DM. The medications
were similar in patients without new-onset DM (28%
treated with thiazide diuretics, 40% with β-adrenergic
blockers, 35% with α-adrenergic blockers, 52% with
ACEIs or ARBs, and 72% with calcium channel
blockers).
Predictors for new-onset diabetes by Cox
proportional hazards analysis
In order to determine the predictors for new-onset
DM in patients with essential hypertension, the opti-
mal cutoff value of each potential parameter was 
constructed by quartiles because of the skewed distri-
bution. Patients with FPG, ALT, or daytime pulse
pressure in the highest quartile were compared with
those in the quartiles below. On the other hand,
patients with the day-night difference in diastolic or
mean BP in the lowest quartile were compared with
those in the quartiles above.
Table 2 shows the potential predictors for new-
onset DM at follow-up. In univariate Cox propor-
tional hazards analysis, FPG>5.8mmol/L (104mg/dL)
(p = 0.014), day-night difference in diastolic BP ≤ 2.9%
(p = 0.025), and ALT > 31 U/L (p = 0.038) were asso-
ciated with increased risk of new-onset DM. By multi-
variate Cox proportional hazards analysis, both FPG >
5.8 mmol/L (relative risk, 10.47; 95% confidence in-
terval, 1.20–91.28; p = 0.034) and ALT > 31 U/L
(p = 0.048) were independent predictors of new-onset
DM in hypertensive patients. Day-night difference in
diastolic BP ≤ 2.9% (p = 0.089) was borderline signifi-
cant as an independent predictor for new-onset DM.
Predictors for new-onset diabetes by 
Kaplan-Meier analysis
Kaplan-Meier analysis was also done to further eluci-
date the relationship between the time course of new-
onset DM and the potential parameters (Figure 1).
Patients with baseline FPG > 5.8 mmol/L (p = 0.001)
(Figure 1A), day-night difference in diastolic BP ≤ 2.9%
(p = 0.009) (Figure 1B) or ALT > 31 U/L (p = 0.018)
(Figure 1C) had significantly more new-onset DM
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Table 2. Predictors for new-onset diabetes mellitus in hypertensive patients
RR (95% CI) p
Univariate Cox proportional hazards regression
FPG > 5.8 mmol/L 15.01 (1.75–128.81) 0.014*
Day-night difference in diastolic BP ≤ 2.9% 6.99 (1.27–38.46) 0.025*
ALT > 31 U/L 6.06 (1.11–33.13) 0.038*
Multivariate Cox proportional hazards regression
FPG > 5.8 mmol/L 10.47 (1.20–91.28) 0.034*
Day-night difference in diastolic BP ≤ 2.9% 4.44 (0.80–25) 0.089
ALT > 31 U/L 5.39 (0.98–29.62) 0.048*
*p < 0.05. RR = relative risk; CI = confidence interval; FPG = fasting plasma glucose; BP = blood pressure; ALT = alanine aminotransferase.
than those without, respectively. In addition, patients
with metabolic syndrome had more new-onset DM
than patients without metabolic syndrome (p = 0.019).
However, metabolic syndrome is complex and het-
erogeneous. Thus, only the individual components of
metabolic syndrome were evaluated.
Approach with multiple risk factors for 
new-onset diabetes in fresh 
hypertensive patients
Further analysis showed that among the 6 patients with
new-onset DM, 1 had baseline FPG ≤ 5.8 mmol/L, 1
had baseline ALT ≤ 31 U/L, and another 1 had day-
night difference in diastolic BP > 2.9%. Only 3 of the
6 patients had all of the 3 indicators mentioned above
at baseline. The other 3 patients had only 2 indicators
at baseline. Accordingly, no single indicator could
predict new-onset DM in all patients. At least 2 of 
the 3 indicators were required to predict future onset
of type 2 DM in newly diagnosed hypertensive patients.
Discussion
It was shown in this study that in addition to FPG,
serum ALT level independently predicted the onset
of type 2 DM in a cohort of originally non-diabetic,
untreated, newly diagnosed hypertensive patients.
Baseline 24-hour BP parameter such as decreased
diurnal change in diastolic BP was also related to the
onset of DM. These findings could be of clinical sig-
nificance since the development of type 2 DM in the
current study was in conjunction with contemporary
antihypertensive treatments used in the real world.
However, no single indicator mentioned above could
predict new-onset DM in all patients. At least 2 of the
3 indicators were required simultaneously for final
risk stratification. Thus, a comprehensive strategy with
both glucose and non-glucose indicators may be jus-
tified to identify patients at risk of future frank DM
even before the guideline-oriented antihypertensive
treatment is given. In concordance with the findings
of a previous study,5 the incidence of hard cardiovas-
cular events was significantly higher in hypertensive
patients with new-onset DM than in those patients
without, suggesting the clinical impact of early risk
stratification for future DM in fresh hypertensives. In
this study, type 2 DM usually developed 2–5 years
after the diagnosis of hypertension. It should be pos-
sible to prevent the onset of DM in individual hyperten-
sive patients via early risk stratification and identification
followed by a tailored interventional strategy in the
future.
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Figure 1. Kaplan-Meier estimation of survival free of new-onset
diabetes mellitus for: (A) fasting plasma glucose (FPG); (B) day-night
diastolic blood pressure (DBP) difference; and (C) serum alanine
aminotransferase (ALT) level. The rate of new-onset diabetes was
significantly increased in patients with baseline FPG > 5.8 mmol/L
(the highest quartile) (p = 0.001 by log-rank test), day-night DBP
difference ≤ 2.9% (the lowest quartile) (p = 0.009 by log-rank
test), or ALT > 31 U/L (the highest quartile) (p = 0.018 by log-rank
test).
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Impacts of FPG on new-onset diabetes mellitus
in hypertensives
It has been suggested that the higher the level of
FPG, the higher the risk of progressing to diabetes,
which might be true even when FPG is < 5.6 mmol/
L.9,22 However, in the present study, the risk of new-
onset DM was significantly increased in those patients
with baseline FPG>5.8mmol/L. Thus, the correlations
between FPG and the future risk of frank DM are not
always constant and linear across different popula-
tions. An artificial threshold of FPG may be required
for highest predictive value for future DM according
to individual clinical condition. Recently, the criteria
of the ADA for IFG that was previously defined as
6.1 mmol/L was further lowered to 5.6 mmol/L.21
However, a more recent study indicated that the
lower cutoff for IFG (ADA 2003 criteria) may result
in a category of IFG that no longer represents a high-
risk state of cardiovascular disease, and that only sub-
jects who convert from IFG to diabetes have a high
risk of cardiovascular mortality.5 Thus, our findings may
have impacts specific to patients with newly diag-
nosed hypertension, in whom a baseline FPG level
>5.8 mmol/L could be associated with a more than
10 times increase in the risk of new-onset DM in the
next 6 years compared to a baseline FPG level ≤ 5.8
mmol/L. This baseline FPG level (5.8 mmol/L) might
be a good cut-off value to identify the risk of future
DM. Given the association between the onset of DM
and cardiovascular events, future prospective follow-
up studies are indicated to determine whether this
baseline FPG level is highly correlated with long-term
prognosis in patients with fresh hypertension.
Impacts of elevated liver enzyme on new-onset
DM in hypertensives
In this study, baseline ALT level, in addition to FPG
level, was another independent predictor of future
onset of type 2 DM in newly diagnosed hypertensive
patients. Though similar findings had been reported
in young healthy subjects as well as in older men,17,23
they were for the first time demonstrated in patients
with fresh hypertension.
It has been suggested that elevated ALT level,
even within normal range, could be associated with
decreased hepatic insulin sensitivity and predict the
development of type 2 DM in originally non-DM
subjects.17 Elevated ALT level may be correlated with
fatty liver and represent visceral fat disposition as a
hallmark of metabolic syndrome.17,23,24 Further, sub-
jects with metabolic syndrome may have a more than
4-fold increase in the risk of future onset of type 
2 DM, which might be explained, at least partially, by
elevated ALT due to increased visceral fat disposi-
tion.23 However, another line of evidence indicates
that elevated serum levels of ALT and γ-glutamyl-
transferase may be only markers of inflammation and
oxidative stress independent of the metabolic syn-
drome.25,26 In the present study, hypertensive patients
with baseline ALT level > 31 U/L had a more than 
5-fold increase in the future risk of new-onset DM. It is
not known whether these patients may have fatty liver
and/or increased oxidative stress since abdominal
sonogram and associated examinations were not per-
formed. However, most of them did not meet the def-
inition of metabolic syndrome. It seems that elevated
ALT level, regardless of fatty liver, rather than the
presence of metabolic syndrome, is a sensitive early
indicator for the consequent development of type 
2 DM in hypertensive patients. Further large-scale
study may need to confirm this issue.
Potential impacts of reduced baseline diurnal
BP changes to new-onset DM in hypertensives
Another interesting finding of this study is the poten-
tial association between reduced diurnal diastolic BP
changes at baseline and future onset of type 2 DM.
Compared to the others, those patients with noctur-
nal reduction in diastolic BP ≤ 2.9% had a more than
4 times increase in the risk of new-onset DM in the
next 6 years. It has been recognized that normal diur-
nal changes in BP consist of a significant, ≥ 10%, reduc-
tion during nighttime. We had previously shown the
presence of glucose intolerance and pancreatic β-cell
dysfunction in young hypertensive subjects with < 10%
nocturnal reduction in daytime BP.15 In these patients,
autonomic dysfunction including sympathetic overac-
tivity and/or parasympathetic withdrawal can also be
found,15,27 which may not only increase insulin resist-
ance but also attenuate the release of insulin as well as
increase hepatic glucose production.28 However, in the
present study, baseline heart rate was similar between
patients with and those without new-onset DM. There-
fore, there is doubt as to whether there is a connec-
tion between the pre-existing autonomic dysfunction
and the late onset of DM in this study.
Recent data showed that inhibition of the renin-
angiotensin system may potentially result in a signifi-
cant reduction in the incidence of type 2 DM in
patients with arterial hypertension.29,30 The HOPE
(Heart Outcomes Prevention Evaluation) study in-
cluded 5,720 patients without known DM (2,837 on
ramipril and 2,883 on placebo).31 The diagnosis of
type 2 DM determined from self-report at follow-
up visits every 6 months during a mean period of 
4.5 years was compared between the 2 groups. 
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One hundred and two individuals (3.6%) in the ramipril
group developed type 2 DM compared with 155 (5.4%)
in the placebo group (odds ratio, 0.66; 95% confidence
interval, 0.51–0.85; p < 0.001). The LIFE (Losartan
Intervention For Endpoint reduction in hyperten-
sion) study was a double-masked, randomized, parallel-
group trial in 9,193 participants aged 55–80 years
with essential hypertension (sitting blood pressure
160–200/95–115 mmHg) and left ventricular hyper-
trophy.32 There was a 25% lower incidence of new-
onset type 2 DM in the losartan group than in the
atenolol group. Among the 6 patients with new-onset
DM in our study, 50% were taking ACEIs or ARBs
before the onset of DM. The medications were simi-
lar in patients without new-onset DM (52% with
ACEIs or ARBs). We do not know whether ACEIs or
ARBs lowered the incidence of new-onset DM in our
current study.
There are several issues that need to be further
addressed. First, since this study’s main aim was to
evaluate the potential predictors of new-onset DM,
the detailed pathological mechanisms were not eluci-
dated. We did not include parameters such as inflam-
matory markers or family history in our study. Further
large-scale studies are indicated to clarify these issues.
Second, in this study, the presence of DM was deter-
mined mainly by the level of FPG according to ADA
criteria.21 It was then impossible to evaluate the pres-
ence of postprandial hyperglycemia or IGT in our
patients. However, plasma value of hemoglobin A1C
was used to confirm the presence of DM once the
FPG level was > 7.0 mmol/L and also to exclude the
presence of DM when FPG > 6.4 mmol/L in 2 sepa-
rate tests. Third, endothelial function assessed by ple-
thysmography could not predict new-onset DM in
our patients. Whether this was due to the limited
sample size, the lack of close causal relationship or the
difference in study methodology is not known. Further
study with different methodology may be considered.
Fourth, it has been suggested that some antihyperten-
sive medications including diuretics and β-blockers
might variably increase the risk of subsequent DM in
hypertensive patients.10–13,30 However, in this study,
antihypertensive medications were similarly given in
patients with and without new-onset DM. Fifth, it
should be noted that the findings of this study were
derived mainly from a primary-prevention cohort of
hypertensive patients with relatively low cardiovascu-
lar risk. There were only 3 strokes and 1 acute myocar-
dial infarction during the whole follow-up period,
giving a < 1% annual incidence of hard adverse events.
It is then impossible to evaluate the individual impacts
of each indicator on long-term prognosis. However,
in patients with new-onset DM, 2 (33%) developed
hard events including stroke and myocardial infarc-
tion whereas only 2 (2%) of the patients without DM
had stroke at follow-up. These results are compatible
with the previous suggestion that new-onset DM,
though usually taking a considerable duration of time
to develop, could be directly associated with cardio-
vascular events.5 Finally, and perhaps most impor-
tantly, the relatively small sample size makes this study
a pilot study only. Further large-scale studies are indi-
cated to confirm the current findings.
In conclusion, in addition to elevated FPG, ele-
vated baseline serum ALT and reduced diurnal dias-
tolic BP changes can also predict the development of
type 2 DM in originally non-diabetic, newly diagnosed
hypertensive patients. Our findings may provide a
rationale for comprehensive risk stratification using
both glucose and non-glucose parameters to identify,
early on, those hypertensive patients at a particular
risk of future DM. In these high-risk patients, regular
metabolic follow-up is essential, and both aggressive
lifestyle modifications and evidence-based pharmaco-
logical interventions may be required to prevent the
onset of type 2 DM and associated cardiovascular
events.33–35 Future community-based studies are indi-
cated to validate the feasibility of such comprehensive
risk stratification in different ethnic cohorts with dif-
ferent patterns of hypertension.
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